• Galectin-1 Impairs Autophagy to Drive Hepatic Steatosis via

  2026-08-06

  This study uncovers a direct mechanistic link between galectin-1 and impaired hepatic autophagy in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). By demonstrating how galectin-1 interacts with FIP200 to disrupt autophagy and promote steatosis and insulin resistance, the findings highlight a novel regulatory axis and potential therapeutic target for metabolic liver disorders.

• EV-Transferred ACLY Drives Monocyte-to-TAM Differentiation i

  2026-08-06

  This study reveals that hepatocellular carcinoma (HCC) cells promote tumor-associated macrophage (TAM) differentiation by transferring ATP-citrate lyase (ACLY) to monocytes via extracellular vesicles. The findings highlight a metabolic mechanism fueling HCC progression and present new avenues for immunometabolic intervention.

• EZ Cap™ Firefly Luciferase mRNA: Molecular Engineering for P

  2026-08-05

  Explore how EZ Cap™ Firefly Luciferase mRNA empowers molecular biology with enhanced stability, translation, and quantitative assay precision. This article reveals the unique impact of Cap1 engineering and LNP delivery optimization for next-generation reporter applications.

• AZD8055: Technical Guidance for mTOR Pathway Inhibition

  2026-08-05

  AZD8055 is a selective, ATP-competitive mTOR inhibitor for preclinical research dissecting mTORC1 and mTORC2 signaling in cancer and metabolic models. It is not suitable for studies prioritizing clinical efficacy endpoints or requiring water solubility. Use AZD8055 for mechanistic analysis of mTOR-regulated pathways under controlled, well-validated laboratory conditions.

• Homoharringtonine Rapidly Clears SARS-CoV-2 Infections In Vi

  2026-08-04

  A recent study demonstrates that homoharringtonine, a cytotoxic alkaloid, can clear SARS-CoV-2 from the upper respiratory tract within 2–4 days using targeted delivery strategies. This work highlights the potential of protein synthesis inhibitors as first-line defenses in future coronavirus epidemics and provides a translational bridge between cancer biology and antiviral research.

• Neuroligin 1 Loss Drives Repetitive Behaviors via Striatal D

  2026-08-04

  This study identifies Neuroligin 1 deficiency in striatal D2 receptor-expressing medium spiny neurons as a key driver of autistic-like repetitive behaviors, mediated through altered PKC signaling and neuronal hyperactivity. The findings clarify cell-type specific mechanisms for restricted and repetitive behaviors in autism spectrum disorder and suggest new intervention points for translational research.

• Recombinant Human IL-15: Optimizing T and NK Cell Assays

  2026-08-03

  Leverage the high bioactivity and purity of Recombinant Human IL-15 (E.coli, Tag Free, Lyophilized) from APExBIO to accelerate T cell activation and NK cell proliferation workflows. This guide translates recent neuroimmune research into actionable protocols and troubleshooting insights for immune response modulation in advanced experimental models.

• SGI-1027: Transforming Epigenetic Modulation in Cancer Resea

  2026-08-03

  This thought-leadership article explores the mechanistic nuance and translational impact of SGI-1027, a potent DNA methyltransferase inhibitor. Integrating advanced experimental insights, competitive benchmarking, and strategic guidance, it clarifies SGI-1027's role in reactivating tumor suppressor genes and shaping the next wave of cancer epigenetics research. The discussion goes beyond standard product descriptions, offering evidence-driven protocols and a forward-looking vision for translational applications.

• iPSC-Derived Multilineage Organoids Enable Pan-Genotype HEV

  2026-08-02

  The reference study establishes iPSC-derived liver, intestinal, and brain organoids as robust models supporting the full life cycle of hepatitis E virus (HEV) across major genotypes. This innovation enables detailed investigation of HEV tissue tropism, host-pathogen interactions, and antiviral drug evaluation in physiologically relevant human systems.

• Irinotecan (CPT-11) in Colorectal Cancer: Molecular Pharmaco

  2026-08-01

  Explore the molecular pharmacology and translational applications of Irinotecan (CPT-11) in colorectal cancer research. This in-depth article uniquely dissects DNA damage induction, metabolic activation, and assay design strategies, offering insights beyond standard protocols.

• Precision qPCR for Translational Oncology: From Mechanism to

  2026-07-31

  Explore how HotStart™ 2X Green qPCR Master Mix empowers translational researchers to dissect oncogenic mechanisms like SNORA38B-driven pathways in NSCLC with unprecedented specificity and workflow efficiency. This article bridges mechanistic insight and strategic guidance, highlighting best practices for real-time PCR gene expression analysis in modern translational studies.

• Palmitic acid (Hexadecanoic Acid): Technical Protocol & QC G

  2026-07-31

  Palmitic acid (SKU N2456) offers a high-purity, well-characterized saturated long-chain fatty acid for researchers investigating lipid metabolism pathways, protein palmitoylation, and metabolic disorder models. It is not suitable for aqueous-based protocols or long-term solution storage, making precise reconstitution and prompt use essential for reproducible results.

• 2X Taq PCR Master Mix: Reliable PCR for Genotyping & Cloning

  2026-07-30

  The 2X Taq PCR Master Mix (with dye) transforms routine DNA amplification, offering robust, error-minimized workflows for genotyping and TA cloning. This article dives deep into protocol enhancements, advanced use-cases, and troubleshooting, while connecting innovations in plant viral diagnostics to streamlined PCR assay design.

• ARCA EGFP mRNA (5-moUTP): Deep Dive into Polyadenylated mRNA

  2026-07-30

  Explore ARCA EGFP mRNA (5-moUTP) as an advanced polyadenylated mRNA tool, delivering superior fluorescence-based transfection control with reduced immunogenicity. This article reveals technical mechanisms, practical assay strategies, and insights from leading mRNA delivery research.

• AG-490 (Tyrphostin B42): Applied JAK2/EGFR Inhibition in Can

  2026-07-29

  AG-490 (Tyrphostin B42) empowers precise dissection of JAK2/STAT and MAPK signaling, with particular strength in modeling tumor-immune interactions such as M2 macrophage polarization in hepatocellular carcinoma. Its robust protocol flexibility and inhibition potency make it indispensable for advanced cancer and immunopathological research.

454 records 9/31 page Previous Next First page 上5页 678910 下5页 Last page